Detection of mutant p53 in hepatocellular cancer from turkey and its correlation with clinicopathologic parameters

Basit Öğe Kaydı
dc.contributor.authorCengiz, C
dc.contributor.authorAkarca, US
dc.contributor.authorGoker, E
dc.contributor.authorYuce, G
dc.date.accessioned2019-10-27T19:00:45Z
dc.date.available2019-10-27T19:00:45Z
dc.date.issued2003
dc.departmentEge Üniversitesien_US
dc.description.abstractThe samples of hepatocellular carcinoma from Turkey, a country with a high prevalence of hepatitis B virus and hepatitis C virus, but low dietary exposure to aflatoxin B1, were examined in order to detect the frequency of mutant p53 and its association with clinical and pathological data. Fifty-two samples of hepatocellular cancer from the patients who were diagnosed in our clinic were included in this study. The mutant p53 protein was searched for by specific enzyme-linked immunosorbent assay. Of 52 patients with hepatocellular carcinoma, 26 (50%) had the mutant p53. The incidence of p53 mutation in hepatocellular cancer patients with chronic liver disease due to hepatitis B virus infection was significantly higher than in those with chronic liver disease due to alcohol, indicating that not alcohol but hepatitis B virus, in fact induces the mutations in p53 gene. In addition, it has been shown that the p53 mutation was significantly associated with the diameter of tumor nodule and the degree of cellular differentiation in hepatocellular cancer. The p53 mutation rate found in our study is concordant for a geography where hepatitis B virus and hepatitis C virus are common. Hepatitis B virus and possibly hepatitis C virus, but not alcohol, should be responsible, to a degree, for the mutational change in p53 protein in hepatocellular cancer patients with chronic liver disease. The p53 mutation is a late event in hepatocarcinogenesis because it is related with cellular differentiation and tumor diameter. The specific ELISA can be a useful screening test in future studies to select the patients for gene therapy using wild-type p53.en_US
dc.identifier.doi10.1023/A:1023031008757en_US
dc.identifier.endpage869en_US
dc.identifier.issn0163-2116
dc.identifier.issue5en_US
dc.identifier.pmid12772781en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage865en_US
dc.identifier.urihttps://doi.org/10.1023/A:1023031008757
dc.identifier.urihttps://hdl.handle.net/11454/37821
dc.identifier.volume48en_US
dc.identifier.wosWOS:000181980500005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKluwer Academic/Plenum Publen_US
dc.relation.ispartofDigestive Diseases and Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecthepatocellular carcinomaen_US
dc.subjectp53 proteinen_US
dc.subjectmutationen_US
dc.subjectenzyme-linked immunosorbent assayen_US
dc.titleDetection of mutant p53 in hepatocellular cancer from turkey and its correlation with clinicopathologic parametersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu